SALVAGETHERAPIES.ORG
2004 Pipeline Report
2004 Antivirals Pipeline
Prepared for Treatment Action Group By Rob Camp current update: 08/28/2004
Phase of Development NRTI NNRTI PI EI* Integrase Inhibitors Maturation Inhibitors Other
Preclinical BPH-218, biphosphonate NRTI, U Pittsburgh Diarylpyrimidines, Tibotec GS-9005, Gilead Benzothiepine and Benzazepine derivatives, CCR5 antagonists, Takeda L-870812, MSD enJS56A1, Escape Inhibitor, U Georgia RWJ67567, p38 inhibitor, U Penn / J&J

Dinucleoside polyphosphates, NRTI "potentiators", U Miami NVP C-8 derivatives, BI VX-385, GSK/Vertex Betulinic Acid Derivatives (BAD), U North Carolina Carbazole derivative, NIID PA-457, Budding inhibitor, Panacos ACH-CIP, capsid inhibitor, Achillion

siRNA molecule, CombiMatrix Tricyclic NNRTI, BMS AG-1859, Pfizer KRH-2731, X4 antagonist, Kureha 810871, GSK Chloroquine, Catholic U, Rome a TRIM5, capsid inhibitor, Dana Farber, NIAID

GS7340, TDF prodrug, Gilead SMP-717, Advanced Life Sciences
PRO-140, monoclonal antibody (MAb), Progenics Styrylquinoline, Bioalliance Pharma Betulinic Acid Derivatives (BAD), U North Carolina CDK inhibitor, Gilead


SMP-610, Advanced Life Sciences
GBV-C, virus that increases chemokines including RANTES (CCR5 blocker), U Iowa V-165, Rega Institute, Belgium
Mifepristone, glucocorticoid antagonist, U Pittsburgh


695634, GSK
15K, co-receptor docking inhibitor, NCI

RSC-1838, GSK/Shionogi




15D, co-receptor docking inhibitor, NCI

siRNA molecule, Nef inhibitor, CombiMatrix




ONO-4128, CCR5 antagonist, GSK/ONO

Resveretol, Egr1 gene activator, NCI




D5, artificial MAb, MSD


Phase I SPD-754, Shire Biochem
PL-100, Procyon BioPharma AMD-070, CXCR4 antagonist, Anormed

HGTV43, gene regulation/editing inhibitor, Enzo




AMD-887, CCR5 antagonist, Anormed

Mycophenylate mofetil, immunosuppressant, U Barcelona




GSK-873140, GSK

VRX496
lentiviral vector
VIRxSYS Corp
Phase I/II or Phase IB MIV-210 (FGV), Medivir/GSK

BMS-043, anti-gp120 blocker, BMS

BAY 50-4798, IL2 selective agonist, Bayer

Reverset (D-D4FC), Pharmasset/Incyte

SCH D, CCR5 antagonist, Schering Plough



SN-1212/1461, mutagenic deoxyribonucleoside, Koronis

SP-01A, Entry Inhibitor, Samaritan Pharma



Racivir (PSI 5004), Pharmasett

TNX-355, Anti-CD4 MAb, Tanox/Biogen


Phase II Elvucitabine (ACH-126), Achillion Calanolide A, Advanced Life Sciences TMC-114/r, Tibotec/J&J PRO-542, attachment inhibitor, Progenics



Amdoxovir (DAPD), Emory University TMC-125 (etravirine), Tibotec/J&J
UK-427,857, CCR5 antagonist, Pfizer



Alovudine (MIV-310), Medivir/BI





Phase III
Capravirine/r, Pfizer/Agouron Tipranavir/r, Boehringer Ingelheim



Notes: EI = entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry.
possibly on hold
Recent news from the XIth Conference on Retroviruses and Opportunistic Infections, San Francisco, 8-11 February, 2004
HIV Treatment Index
TAG index - Last modified 08/31/2004

CONTACT US
Nelson Vergel, Director
Program for Wellness Restoration, PoWeR, A 501 (c) 3 non profit national organization

Our web sites:
http://www.medibolics.com/
http://www.facialwasting.org/
http://www.salvagetherapies.org/
Free Listservers
Send a blank email to:
pozhealth-subscribe@yahoogroups.com
fuzeonsupport-subscribe@yahoogroups.com